

National Board of Examinations

Question Paper Name :	DNB Pharmacology Paper3
Subject Name :	DNB Pharmacology Paper3
Creation Date :	2022-06-25 17:21:34
Duration :	180
Share Answer Key With Delivery Engine :	No
Actual Answer Key :	No

DNB Pharmacology Paper3

Group Number :	1
Group Id :	3271871163
Group Maximum Duration :	0
Group Minimum Duration :	180
Show Attended Group? :	No
Edit Attended Group? :	No
Break time :	0
Group Marks :	100
Is this Group for Examiner? :	No
Examiner permission :	Cant View
Show Progress Bar? :	No

DNB Pharmacology Paper3

Section Id :	3271871166
Section Number :	1

Section type : Offline
Mandatory or Optional : Mandatory
Number of Questions to be attempted : 10
Section Marks : 100
Enable Mark as Answered Mark for Review and Clear Response : Yes
Maximum Instruction Time : 0
Sub-Section Number : 1
Sub-Section Id : 3271871170
Question Shuffling Allowed : No

Question Number : 1 Question Id : 32718710682 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Please write your answers in the answer booklet within the allotted pages as follows:-

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

1. Describe regulation of experimental animal research in India and alternatives to animal experiments. [5+5]

Question Number : 2 Question Id : 32718710683 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Describe the models available for screening a drug for anti-platelet activity. [10]

Question Number : 3 Question Id : 32718710684 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Describe battery of tests for neurobehavioral assessments in an animal experiment study for neurological disease. [10]

Question Number : 4 Question Id : 32718710685 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Discuss the preclinical models for evaluation of anti-hypertensive activity of a new molecule. [10]

Question Number : 5 Question Id : 32718710686 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Describe about statistical significance versus clinical significance with examples. [5+5]

Question Number : 6 Question Id : 32718710687 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Discuss the screening models of anti-leprosy drugs. [10]

Question Number : 7 Question Id : 32718710688 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Describe various parametric tests used in reasearch. [10]

Question Number : 8 Question Id : 32718710689 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Describe hybridoma technology and its clinical significance with future applications. [10]

Question Number : 9 Question Id : 32718710690 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Explain Type I and type II errors. [10]

Question Number : 10 Question Id : 32718710691 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Discuss Organization of Economic Corporation and Development(OECD) and Non-clinical toxicity studies for drug development. [5+5]